|
|
 |
|
Viewing report
|
|
|
|
Competitor Analysis: Herpes Virus Vaccines and Therapeutics
La Merie Publishing, June 2010, Pages: 36
The present Competitive Intelligence Report about Herpes Virus Vaccines & Therapeutics provides a competitor evaluation in the field of prophylactic vaccines and therapeutic antibodies and small molecules against infection caused by herpes simplex virus (HSV) type 1 and/or type 2 and varicella zoster virus (VZV) or human herpes virus type 3 (HHV-3) as of June 2010. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
Herpes simplex virus 1 and 2 (HSV-1 and HSV-2), also known as Human herpes virus 1 and 2 (HHV-1 and -2), are two members of the herpes virus family that infect humans. HSV-1 and HSV-2 cause the viral disease herpes simplex which can be categorized into one of several distinct disorders based on the site of infection: oral herpes with the visible symptoms of cold sores or fever blisters, genital herpes and other forms including ocular herpes (keratitis).
Varicella zoster virus (VZV) is another of eight herpes viruses known to infect humans. It commonly causes chicken-pox in children and both shingles and postherpetic neuralgia in adults and rarely in children. Varicella zoster virus is known by many names, including: chickenpox virus, varicella virus, zoster virus, and human herpes virus type 3 (HHV-3).
The report includes a compilation of marketed and currently active projects in development of vaccines, antibodies and small molecules targeting herpes simplex virus type 1 or type 2 (HSV-1 or HSV-2) and varicella zoster virus (VZV) or human herpes virus type 3 (HHV-3) for prophylaxis and treatment of oral herpes, genital herpes, chickenpox (varicella) and herpes zoster, respectively. In addition, the report lists company-specific R&D pipelines of Herpes Virus Vaccines & Therapeutics. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Herpes Simplex Virus Treatment - Global Strategic Business Report
Herpes Market to 2018 - Genericization Compels Competitors Seeking Differentiation to Adopt Novel Drug Delivery Technologies
ENT Infections: An Atlas of Investigation and Management
Herpes Simplex Infections - Pipeline Review, H1 2012
Herpes Simplex Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Dealmaking and Industry Outlook: Antivirals
Competitor Analysis: Anti-Infective Antibodies
Herpes Zoster (Shingles) - Pipeline Review, H1 2012
Emerging Microbiology Tests and Companies Developing New Technologies and Products
Herpes Simplex Infections - Pipeline Review, H2 2011
|
|
|
|
